Zota Health Care Limited is signaling a notable governance shift as it taps Mahaveer Dhariwal to join its board as an Independent Director, effective September 3, 2026. The appointment, disclosed in the company’s board-level deliberations, positions Dhariwal as a Non-Executive Independent Director to bolster governance and board independence ahead of the company’s forthcoming AGM. While the nomination awaits shareholder approval at the AGM, the move underscores Zota Health’s emphasis on strengthening oversight and governance as it scales its portfolio and footprint.
At the same time, the company is renewing its leadership engine. The board has re‑appointed Moxesh Ketanbhai Zota as Managing Director for another five-year term, running from October 7, 2026 to October 6, 2031. The remuneration package for the MD includes a fixed salary of Rs 60 lakh per annum, a 0.20% commission on annual consolidated turnover, and annual sitting fees of Rs 5,000 per board or committee meeting. This arrangement sits within an overall cap framework for promoter-director remuneration through 2030, reflecting the company’s approach to balancing growth incentives with governance guardrails.
Additionally, Ketankumar Chandulal Zota, the Non-Executive Chairman and a prominent promoter figure, is set to receive a fixed remuneration package for the 2026-27 year structured as a profit-related commission of 0.30% of annual consolidated turnover, complemented by typical board sitting fees of Rs 5,000 per meeting. The board has also highlighted a broader framework for related-party transactions that includes ongoing approvals for salary-related RPTs and a compliant arm’s-length structure, underscoring a continuing emphasis on transparent governance within a closely-held business. Taken together, these moves reflect Zota Health Care’s intent to reinforce executive continuity, while strengthening independent oversight as it navigates a period of expansion and consolidation.